Pillstats
Rx only · Capsule · Oral

Valbenazine

Brands: Ingrezza · Ingrezza Sprinkle · Valbenazine Tosylate

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US6 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)1918219
US makers1 labelers
Packages6
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$79.13$158.26$237.40$316.53Oct 2025May 2026Jul 2026
$275.197
Latest avg · Jul 22, 2026
-0%
Since Oct 1, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

13K26K39K52K2025 Q12025 Q22025 Q32025 Q42026 Q1
43K
Rx · 2026 Q1
1.3M
Units dispensed
+10%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Neurocrine Biosciences, Inc.unknown6SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.